Clinical Trial

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.
Trial Details
NCT Number NCT06971913
Lead Sponsor Peking University People's Hospital
Conditions SLE (Systemic Lupus), CMV
Enrollment 100 participants
Start Date 2025-05-20
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-14